Literature DB >> 15712003

[Therapy with radioisotopes in oncology. Palliative and curative approaches].

H-J Biersack1, S Ezziddin, J Risse, H Bender, H Palmedo.   

Abstract

For more than 50 years now, nuclear medicine has offered therapeutic procedures in oncology. These comprise bone pain palliation in bone metastases of prostate and breast cancer. For more than 20 years now, metaiodobenzylguanidine (mIBG) has been used to treat neuroendocrine tumors. Ten years ago, somatostatin analogues such as Y-90 Dotatoc became available for the treatment of somatostatin receptor-positive tumors. The intracavitary injection of radiocolloids has been well known for 5 decades now and can be used in malignant effusions. Invasive procedures such as intra-arterial injection of I-131 lipiodol may be applied in multifocal, nonresectable hepatocellular carcinoma. Beyond that, intratumoral injection of radioisotopes may be used in cutaneous metastases. Radioimmunotherapy using labeled tumor antibodies is now also available, especially in patients with non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712003     DOI: 10.1007/s00482-003-0293-z

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  8 in total

1.  Yttrium-90-labelled somatostatin-analogue for cancer treatment.

Authors:  A Otte; J Mueller-Brand; S Dellas; E U Nitzsche; R Herrmann; H R Maecke
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

Review 2.  Nuclear medicine therapy of pheochromocytoma and paraganglioma.

Authors:  L Troncone; V Rufini
Journal:  Q J Nucl Med       Date:  1999-12

3.  Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.

Authors:  B G Taal; C Hoefnagel; H Boot; R Valdés Olmos; M Rutgers
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

4.  Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

Authors:  A H Laing; D M Ackery; R J Bayly; R B Buchanan; V J Lewington; A J McEwan; P M Macleod; M A Zivanovic
Journal:  Br J Radiol       Date:  1991-09       Impact factor: 3.039

5.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Authors:  S M Tu; R E Millikan; B Mengistu; E S Delpassand; R J Amato; L C Pagliaro; D Daliani; C N Papandreou; T L Smith; J Kim; D A Podoloff; C J Logothetis
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

6.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

7.  Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.

Authors:  Holger Palmedo; Agnieska Manka-Waluch; Peter Albers; Ingo G H Schmidt-Wolf; Michael Reinhardt; Samer Ezziddin; Alexius Joe; Roland Roedel; Rolf Fimmers; F F Knapp; Stefan Guhlke; Hans-Jurgen Biersack
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

8.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.